Valneva SE (VALN) Interest Expenses (2021 - 2026)
Valneva SE's (VALN) quarterly Interest Expenses came in at -$6.0 million in Q1 2026, up 5.21% year-on-year from -$5.7 million in Q1 2025, and down 120.82% quarter-over-quarter from $28.6 million in Q4 2025.
Valneva SE (VALN) Interest Expenses (2021 - 2026) Analysis & Trends
Valneva SE has disclosed Interest Expenses across 6 years of filings, most recently posting -$6.0 million for Q1 2026.
- Interest Expenses for Q1 2026 came in at -$6.0 million, up 5.21% year-over-year; the trailing twelve-month figure through Mar 2026 was $50.1 million (up 80.7% YoY), and the FY2025 annual result was $48.8 million, up 90.18% from the prior year.
- Interest Expenses came in at -$6.0 million for Q1 2026 at Valneva SE, down from $28.6 million in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $38.5 million in Q4 2023 to a low of -$7.7 million in Q1 2024.
- The 5-year median for Interest Expenses is -$4.1 million (2023), against an average of $6.7 million.
- Peak annual rise in Interest Expenses reached 932.23% in 2024, while the deepest fall reached 82.52% in 2024.
- Valneva SE's Interest Expenses stood at $33.1 million in 2022, then grew by 16.36% to $38.5 million in 2023, then tumbled by 82.52% to $6.7 million in 2024, then soared by 325.35% to $28.6 million in 2025, then tumbled by 120.82% to -$6.0 million in 2026.
- The last three Interest Expenses figures came in at -$6.0 million (Q1 2026), $28.6 million (Q4 2025), and $33.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | -5.50 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | 61,000.00 |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | -332,000.00 |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | -2,753.00 |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | - |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | -5.58 Mn |
| 10 | Valneva SE | 167.33 Mn | 44.10 Mn | 5.08 Mn | -5.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.96 Mn |
| Mar 31, 2026 | -5.96 Mn |
| Dec 31, 2025 | 28.64 Mn |
| Dec 31, 2025 | 28.64 Mn |
| Sep 30, 2025 | 33.77 Mn |
| Sep 30, 2025 | 33.77 Mn |
| Jun 30, 2025 | -6.35 Mn |
| Jun 30, 2025 | -6.35 Mn |
| Mar 31, 2025 | -6.29 Mn |
| Mar 31, 2025 | -6.29 Mn |
| Dec 31, 2024 | 6.73 Mn |
| Dec 31, 2024 | 6.73 Mn |
| Sep 30, 2024 | 32.60 Mn |
| Sep 30, 2024 | 32.60 Mn |
| Jun 30, 2024 | -5.32 Mn |
| Jun 30, 2024 | -5.32 Mn |
| Mar 31, 2024 | -7.65 Mn |
| Mar 31, 2024 | -7.65 Mn |
| Dec 31, 2023 | 38.52 Mn |
| Dec 31, 2023 | 38.52 Mn |